Updated
Chronic kidney disease: Asian pipelines and global competitors
As of 2026-11-14, Asian CKD programs include UnicoCell’s ELIXCYTE-CKD cell therapy and the IgA-nephropathy products sibeprenlimab from Otsuka and NEFECON from Everest Medicines. Global comparators include investigational balcinrenone/dapagliflozin and finerenone. IgA nephropathy, diabetic kidney disease and broader CKD are distinct populations; indications and approval status are separated below.
Selected kidney-protection and disease-modifying approaches; ACE inhibitors, ARBs, SGLT2 monotherapies and dialysis-complication medicines are not exhaustively covered.
Asian companies
| Asset | Company | Mechanism / route | Stage | Indication | Deal / rights | Latest verified record | Sources |
|---|---|---|---|---|---|---|---|
ELIXCYTE-CKD | UnicoCell (Taiwan) | Allogeneic adipose-derived mesenchymal stromal cells IV | Phase 1/2 completed; Phase 3 IND submitted | Chronic kidney disease | No verified deal terms identified | The 10-01 release confirms continued CKD development; its cell export license is a separate matter, not CKD marketing approval. | |
sibeprenlimab / VOYXACT | Otsuka / Visterra | Anti-APRIL antibody SC | US accelerated approval; confirmatory data reported | Adults with primary IgA nephropathy at risk of progression | No verified deal terms identified | Presented final two-year Phase 3 VISIONARY results at ASN; accelerated approval and final data are separate milestones. | |
NEFECON / targeted-release budesonide | Everest Medicines; originated by Calliditas | Ileum-targeted release budesonide Oral | Full approval in China | Primary IgA nephropathy | Regionally licensed product; deal amounts not verified | The product page records full China approval in 2025-04; no later dated milestone for this product is supplied on that page. |
Global comparators
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
balcinrenone / dapagliflozin | AstraZeneca | Non-steroidal MRA / SGLT2 inhibition Oral | Phase 3 | Advanced CKD; separate HF-with-CKD program | The 10-30 pipeline snapshot lists Phase 3; the snapshot is not evidence of trial initiation on that date. | |
finerenone / KERENDIA | Bayer | Non-steroidal mineralocorticoid receptor antagonist Oral | Approved in diabetes-associated CKD; non-diabetic CKD sNDA accepted | Diabetic / non-diabetic CKD considered separately | Announced FDA acceptance of the non-diabetic CKD sNDA; acceptance is not approval. |
Events in the last 90 days
2026-08-17 – 2026-11-14
balcinrenone / dapagliflozin
The 10-30 pipeline snapshot lists Phase 3; the snapshot is not evidence of trial initiation on that date. Primary source
sibeprenlimab / VOYXACT
Presented final two-year Phase 3 VISIONARY results at ASN; accelerated approval and final data are separate milestones. Primary source
finerenone / KERENDIA
Announced FDA acceptance of the non-diabetic CKD sNDA; acceptance is not approval. Primary source
ELIXCYTE-CKD
The 10-01 release confirms continued CKD development; its cell export license is a separate matter, not CKD marketing approval. Primary source
Sources and downloads
- UnicoCell October update — 2026-10-01
- UnicoCell CKD Phase 1/2 publication and IND — 2026-02-06
- Otsuka VISIONARY final results — 2026-10-23
- Otsuka FDA accelerated approval — 2025-11-26
- Everest official product page — Undated
- AstraZeneca pipeline snapshot — 2026-10-30
- Bayer non-diabetic CKD sNDA acceptance — 2026-10-09
Information cutoff 2026-11-14